A Chemotherapy-Free Era in Leukemia: Ponatinib Plus Blinatumomab Proves Superior in Ph-Positive ALL

A Chemotherapy-Free Era in Leukemia: Ponatinib and Blinatumomab Outperform Imatinib plus Chemotherapy in Ph-Positive ALL

Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is one of the most common ALL subtypes in adults and has historically been one of the hardest to treat. In the phase 3 ALL2820 trial from the Italian GIMEMA group, a regimen containing no chemotherapy at all, ponatinib + blinatumomab, raised 2-year event-free survival from 67% to 86% compared with standard imatinib + chemotherapy in newly diagnosed adults. The results were published in the New England Journal of Medicine in October 2026. Overall survival was also higher in the chemotherapy-free arm (90% vs 85%), but the difference was not statistically significant. We have previously covered bispecific antibodies and CAR-T therapy and lymphomas.

Why does this matter?

Acute lymphoblastic leukemia is a blood cancer caused by the uncontrolled growth of immature lymphocyte precursors in the bone marrow. About one in four adults with ALL, and close to half of older patients, have the Philadelphia chromosome, formed by an exchange of material between chromosomes 9 and 22, and the BCR::ABL1 fusion protein it produces (genetic changes in cancer). This protein acts like a "switch stuck in the on position" that keeps driving the cell to divide.

Before the 2000s, the outlook for Ph-positive ALL was very poor; intensive chemotherapy and, where possible, bone marrow transplantation were the only options. Adding tyrosine kinase inhibitors (TKIs) that block BCR::ABL1 (imatinib, dasatinib, ponatinib) to chemotherapy improved results considerably. However, intensive chemotherapy (with many side effects, from nausea and vomiting to infection) carries a risk of infection, neutropenia and treatment-related loss of life, particularly in older patients. GIMEMA ALL2820 was the first randomized phase 3 trial to test whether removing chemotherapy entirely and replacing it with a targeted drug and an immune-based antibody works better than standard treatment.

What is Ph-positive ALL?

Ph-positive acute lymphoblastic leukemia is the type of ALL in which the leukemia cells carry the Philadelphia chromosome, the result of an exchange of material between chromosomes 9 and 22. This change produces a protein called BCR::ABL1 that keeps driving the cell to divide. It accounts for about a quarter of adult ALL cases, and its frequency rises with age. Tyrosine kinase inhibitors that block BCR::ABL1 are the cornerstone of its treatment.

The two drugs used in the regimen

• Ponatinib: A third-generation tyrosine kinase inhibitor taken by mouth. It is active against many BCR::ABL1 resistance mutations, including T315I, which makes cells resistant to imatinib and dasatinib. Its main side effect of concern is cardiovascular events such as arterial occlusion; the risk rises with dose and age.
• Blinatumomab: A bispecific T-cell engager antibody that binds CD19 on leukemia cells with one arm and CD3 on T lymphocytes with the other, directing the patient's own T cells to the leukemia cells. It is given as a continuous intravenous infusion over 28 days; its main side effects are cytokine release syndrome (fever, low blood pressure) and neurologic side effects, which resemble those of other immune-based therapies.

How was GIMEMA ALL2820 conducted?

Results

At 24 months, event-free survival was 86% in the chemotherapy-free arm and 67% in the standard arm (p<0.001). The difference in molecular event-free survival was also marked (68% vs 42%). Overall survival was higher in the chemotherapy-free arm (90% vs 85%), but this difference was not statistically significant. One reason may be that patients in the standard arm with an inadequate response could cross over to chemotherapy-free treatment: residual disease cleared in 20 of the 31 patients (65%) who crossed over.

Chemotherapy-free treatment produced faster and deeper responses. Complete hematologic response at the end of induction was 94% vs 79%, and molecular response after blinatumomab consolidation was 71% vs 49%. The cumulative incidence of relapse was 5% vs 13%. The only relapse in the chemotherapy-free arm was in the central nervous system; in this arm, drug delivery into the spinal fluid (intrathecal therapy) had been increased to 15–18 administrations, compared with 2 in the standard arm.

Stem cell transplantation

After first complete remission, allogeneic hematopoietic stem cell transplantation was performed in 19% of patients in the chemotherapy-free arm and 26% in the standard arm. Overall, 45 of 211 patients (21%) underwent transplantation. Transplantation was not routine; it was offered to patients selected according to MRD status and genetic risk profile. This suggests that fewer patients may need a transplant in the future.

Safety

Grade 3 or higher serious adverse events were less frequent in the chemotherapy-free arm (34% vs 47%), and loss of life during induction was markedly less common (3% vs 9%). In both arms, the most common serious adverse events were infections. Cardiovascular events were rare; they were seen only in patients receiving 45 mg of ponatinib and mostly in older patients.

From congress presentation to journal publication: what changed?

The advantage in event-free survival is robust in both analyses. However, the overall survival difference presented as significant at the congress lost its significance in the peer-reviewed publication. This is another reminder that congress results should not be read as final data.

How should the results be interpreted?

Strengths

• The first randomized phase 3 trial comparing a chemotherapy-free approach with standard treatment.
• Event-free survival, relapse, depth of response and toxicity: all main measures point in the same direction.
• Less loss of life during induction and fewer serious adverse events in the chemotherapy-free arm; this matters especially for older patients.
• Transplant decisions were based on MRD and genetic risk; fewer patients underwent transplantation.
• An academically funded trial (supported by Italian cancer research foundations).

Points to keep in mind

• Overall survival: The difference was not significant; the crossover design may make overall survival look similar between arms. Longer follow-up is needed.
• Short follow-up: Median 2 years; late relapses and long-term cardiovascular risk are unknown.
• Open-label design: Patients and physicians knew which treatment was given; however, only 2 patients withdrew consent.
• Event definition: Event-free survival also counts "failure to achieve complete molecular response" as an event, which naturally favors the arm producing deeper responses.
• Comparator arm: The standard arm used imatinib; there was no comparison with ponatinib or dasatinib + chemotherapy.
• Single country: All patients were from Italy; the results need to be confirmed in other health care systems.
• Practical challenge: Blinatumomab is given as a 28-day continuous infusion and requires a portable pump and home infusion support.

What does this mean in practice?

• Chemotherapy-free treatment is a strong option: In newly diagnosed Ph-positive ALL, ponatinib + blinatumomab was found to be more effective and less toxic than chemotherapy-based standard treatment. International guidelines are expected to be updated in light of this result.
• Especially for older and frail patients: The benefit of a chemotherapy-free approach may be even greater in patients who could not tolerate intensive chemotherapy.
• Cardiovascular risk should be assessed: Before ponatinib, risk factors such as blood pressure, cholesterol, blood sugar and smoking should be reviewed; a lower dose should be considered in older patients.
• MRD monitoring is essential: Treatment decisions are based on residual disease measured by BCR::ABL1 in the bone marrow. We have also discussed the concept of residual disease using ctDNA in solid tumors.
• Central nervous system prophylaxis: With chemotherapy-free treatment, an adequate number of preventive intrathecal doses into the spinal fluid is important.
• Not everyone may need a transplant: Transplantation may be avoided in patients who achieve MRD negativity and do not have a high-risk genetic profile; this decision should be made at an experienced hematology center.

Practical advice for patients and families

• If you have been diagnosed with ALL, ask whether your leukemia cells have been tested for the Philadelphia chromosome (BCR::ABL1) and how the result will affect your treatment.
• Discuss chemotherapy-free treatment options, access to the drugs and clinical trials with your hematologist; seek a second opinion if needed.
• During blinatumomab, tell your care team right away if you develop fever, chills, dizziness, difficulty speaking, hand tremor or any change in alertness.
• While taking ponatinib, seek emergency care for symptoms such as chest pain, shortness of breath, leg pain and swelling, or sudden difficulty speaking or seeing (signs of a heart attack).
• Protect yourself from infection; seek care promptly if you have a fever, and plan your vaccinations and preventive medicines with your care team.
• During and after treatment, report fatigue and other symptoms; stay in regular follow-up for long-term side effects.

Frequently asked questions

Can Ph-positive ALL be treated without chemotherapy?

Yes, a growing body of evidence supports this. In the phase 3 GIMEMA ALL2820 trial, ponatinib + blinatumomab raised 2-year event-free survival from 67% to 86% compared with imatinib + chemotherapy and caused fewer serious adverse events. However, this combination is not yet approved as first-line treatment.

Does ponatinib + blinatumomab help patients live longer?

Two-year overall survival was 90% in the chemotherapy-free arm and 85% in the standard arm; the difference was not statistically significant. Allowing patients in the standard arm to cross over to chemotherapy-free treatment when needed may have narrowed the difference; longer follow-up is needed.

Does this treatment remove the need for a bone marrow transplant?

Not for everyone. In the trial, transplantation was recommended only for patients with persistent residual disease or a high-risk genetic profile; 19% of patients in the chemotherapy-free arm underwent transplantation. The decision to transplant should be individualized.

Is this treatment available in Turkey?

Both drugs are licensed in Turkey; however, their combined use as first-line treatment for newly diagnosed Ph-positive ALL is not covered by the marketing authorization or SGK reimbursement and requires off-label approval.

Glossary

Acute lymphoblastic leukemia (ALL)

A blood cancer in which immature lymphocyte precursors grow uncontrollably in the bone marrow.

Philadelphia chromosome / BCR::ABL1

A fusion gene formed by an exchange of material between chromosomes 9 and 22 that keeps driving the cell to divide.

Tyrosine kinase inhibitor (TKI)

A targeted oral drug that blocks growth signals such as BCR::ABL1 (imatinib, dasatinib, ponatinib).

Bispecific antibody

An antibody that binds two targets at once, directing immune cells to cancer cells.

Measurable residual disease (MRD)

Leukemia cells remaining after treatment that cannot be seen under the microscope but are detected by sensitive molecular methods.

Event-free survival (EFS)

The time that passes without an event such as relapse, lack of response to treatment, serious toxicity or loss of life.

Allogeneic stem cell transplantation

Giving a patient blood-forming stem cells collected from another donor.

IKZF1-plus

A genetic profile in which a deletion in the IKZF1 gene is accompanied by other genetic changes; it is associated with a less favorable outlook.